NDAINTRAVENOUSPOWDERPriority Review
Approved
Sep 2003
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
20
Data completeness
5/8 — Partial
Priority Review
CUBICIN RF (daptomycin) by Merck & Co. is 12. Approved for bacteremia, pneumonia, bacterial, soft tissue infections and 2 more indications. First approved in 2003.
Drug data last refreshed 20h ago
Mechanism of Action
12.1 Mechanism of Action Daptomycin is an antibacterial drug [see ]. 12.2 Pharmacodynamics Based on animal models of infection, the antimicrobial activity of daptomycin appears to correlate with the AUC/MIC (area under the concentration-time curve/minimum inhibitory concentration) ratio for certain…
Worked on CUBICIN RF at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.